Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Richtig, Georg; Hoeller, Christoph; Wolf, Martin; Wolf, Ingrid; Rainer, Barbara M; Schulter, Günter; Richtig, Markus; Grübler, Martin R; Gappmayer, Anna; Haidn, Thomas; Kofler, Julian; Huegel, Rainer; Lange-Asschenfeldt, Bernhard; Pichler, Martin; Pilz, Stefan; Heinemann, Akos; Richtig, Erika.
PLoS One; 13(10): e0204729, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30273398

INTRODUCTION:

Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects.

METHODS:

In this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25).

RESULTS:

40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank).

CONCLUSIONS:

The BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.
Selo DaSilva